Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

107.23 -0.81 (-0.75%)

Streaming Delayed Price Updated: 10:57 AM EDT, Jul 29, 2026 Add to My Watchlist

Price and Volume

Volume	56,075
Open	107.62
Bid (Size)	106.92 (100)
Ask (Size)	107.54 (100)
Prev. Close	108.04
Today's Range	106.37 - 108.40
52wk Range	74.50 - 122.20
Shares Outstanding	66,684,077
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

July 21, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

July 08, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	+2.1%	+2.1%
1 Month	-2.6%	-2.6%
3 Month	+27.4%	+27.4%
6 Month	+1.6%	+1.6%
1 Year	+25.2%	+25.2%

More News

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

June 15, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

June 13, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates ↗

May 05, 2026

Via Chartmill

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

June 12, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

May 29, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

May 28, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

May 26, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

May 12, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

My Top 3 Stocks to Buy in May ↗

May 07, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results ↗

May 06, 2026

Via Benzinga

Rhythm (RYTM) Q1 2026 Earnings Call Transcript ↗

May 06, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

May 06, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday ↗

May 05, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 05, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

May 04, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

May 01, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

April 09, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal

April 07, 2026

Via MarketMinute

Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit

April 07, 2026

Via Finterra

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar

April 06, 2026

Via MarketMinute

Rhythm Pharmaceuticals Announces Changes to Board of Directors

April 03, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Is This Weight Loss Drug Stock a Buy After a New Approval? ↗

March 31, 2026

Via The Motley Fool

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

March 26, 2026

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?

Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market

What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?

The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 107.23

When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 07/29/26 10:57 AM ET

What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 7.15B

How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?

Rhythm Pharmaceuticals, Inc. - Common Stock has 7B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.